Related Experiment Videos
Restenosis: Intracoronary Brachytherapy
Douglas E. Drachman1, Daniel I. Simon
1Cardiovascular Division, Department of Medicine, Brigham and Women's Hospital, 75 Francis Street, Boston, MA 02115, USA. dsimon@rics.bwh.harvard.edu
Insights
Intracoronary radiation (brachytherapy) effectively treats in-stent restenosis after coronary interventions, reducing re-narrowing and repeat procedures. However, it increases late stent thrombosis risk, necessitating careful patient selection and extended antiplatelet therapy.
Area of Science:
- Cardiology
- Interventional Cardiology
- Medical Physics
Background:
- In-stent restenosis is a major limitation following percutaneous coronary intervention for symptomatic coronary artery disease.
- Conventional treatments for in-stent restenosis have limited success rates (50-80%).
Purpose of the Study:
- To evaluate the efficacy and safety of intracoronary radiation (brachytherapy) for treating in-stent restenosis.
- To identify patient subgroups who may benefit most from brachytherapy.
Main Methods:
- Intracoronary brachytherapy targets cellular proliferation in the neointima causing in-stent restenosis.
- Clinical trials assessed angiographic restenosis and target vessel revascularization rates.
Main Results:
- Brachytherapy reduced angiographic restenosis by 50-60% and target vessel revascularization by 40-50%.
- Benefits were notable in patients with diabetes, long lesions, or saphenous vein bypass graft lesions.
- An increased risk of late stent thrombosis and need for prolonged antiplatelet therapy were observed.
Conclusions:
- Intracoronary brachytherapy is an effective treatment for in-stent restenosis, particularly in specific patient groups.
- The evolving role of brachytherapy must consider advances in drug-eluting stents for restenosis prevention.
Abstract:
Though interventional strategies have revolutionized the management of patients with symptomatic coronary artery disease, in-stent restenosis has emerged as the single most important limitation of long-term success following percutaneous coronary intervention. Once present, in-stent restenosis is extraordinarily difficult to treat, with conventional revascularization techniques failing in 50% to 80% of patients. Intracoronary radiation, or brachytherapy, targets cellular proliferation within the culprit neointima. Clinical trials have demonstrated that brachytherapy is a highly effective treatment for in-stent restenosis, reducing angiographic restenosis by 50% to 60% and the need for target vessel revascularization by 40% to 50%. The benefits of intracoronary brachytherapy may be particularly pronounced in certain patient subgroups (eg, those with diabetes, long lesions, or lesions in saphenous vein bypass grafts), but comes at the cost of an increased rate of late stent thrombosis and the need for extended antiplatelet therapy. The role of brachytherapy in the arsenal of the interventional cardiologist will continue to evolve, particularly in light of the unprecedented recent advances with the use of drug-eluting stents for restenosis prevention.